3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
64
Neoplasms
8
Sarcoma
6
Ovarian Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Glioma
4
Carcinoma, Non-Small-Cell Lung
4
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma
3
Liposarcoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Kidney Neoplasms
2
Interventions
Tamoxifen
2
Paclitaxel
2
pyrotinib
1
pembrolizumab
1
palbociclib
1
iniparib
1
darolutamide
1
Thioctic Acid
1
Pentoxifylline
1
Metformin
1
Letrozole
1
Doxorubicin
1
Cyclophosphamide
1
Capecitabine
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Female
×
palbociclib
×
Clear all
NCT03065621
2023-04-19
NeoRHEA
Jules Bordet Institute
Phase 2
Completed
100 enrolled